The multidisciplinary European Expert Group on Orphan Drug Incentives (OD Expert Group) has developed fourteen innovative proposals along the entire lifecycle of orphan drug development to address the unmet needs in rare diseases. With over ninety percent of patients without a centrally approved treatment option,… read more
The objective of EUCOPE’s Advanced Diagnostics Working Group The Advanced Diagnostics Working Group is made up of diagnostics companies that have come together to ensure Europe will be able to draw benefit from the significant advances that have been made in genomic testing. The group… read more
On 7 May, the European Commission opened its public consultation on the revision of EU rules on medicines for children and rare diseases. The consultation, aimed at stakeholders and members of the general public, including patients and doctors, will explore several options to address the shortcomings… read more
EUCOPE has the pleasure to participate to the 1st International Conference on Rare Diseases organised under the patronage of H.E. the President of the Hellenic Republic. The event, entitled “Building a Pathway from Diagnosis to Access” will take place virtually on the first and second… read more
As demonstrated by the fight against COVID-19, Artificial Intelligence (AI) has the potential to drive change and improve efficiency and accessibility in healthcare. From compounds design in medicines development to faster patient screening and diagnosis to hospital management (to name but a few applications), AI-based… read more
The recent years have seen a number of high-end innovative therapies becoming accessible to patients in Europe. These products offer groundbreaking new opportunities to patients living with rare diseases or cancer, with the capacity of often one-time disease-modifying and potentially curative treatments. This new generation… read more
Join experts on 27 January, to discuss how a fit-for-purpose environment can help develop AI and the digitalisation of healthcare. Hearing the priorities of the Portuguese presidency and the European Commission’s plans on digital health, panellists will share ideas on: How can the EU facilitate… read more
Following a successful launch event, the TRANSFORM MEP Interest Group, a multi-stakeholder alliance of Members of European Parliament, patient groups, academia and industry, published two important documents to lay the foundations of an open discussion on key priorities for gene and cell therapies, namely a… read more
According to the MHRA Guidance, up until 31 December 2021, medicines can be supplied from Great Britain (GB) to Northern Ireland (NI) with a “pragmatic approach” to applying EU rules on importation and unique identifier requirements. Outside of these two areas, medicines supplied to NI have… read more
Aware of the complex European policy landscape that will keep policymakers busy in the months to come, EUCOPE wanted to discuss the European innovation leadership in the pharmaceutical sector and discover how the European Union and Member States can support pharmaceutical innovation in Europe. On… read more
Keep up-to-date on all of the most pertinent policy files and regulatory news around the world of European health technologies with our monthly newsletter – the Innovation Eye-View
You are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
You are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
You are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.